| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23026 |
| Drug | Efgartigimod alfa |
| Brand | Vyvgart® |
| Indication | Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. |
| Assessment Process | |
| Rapid review commissioned | 12/05/2023 |
| Rapid review completed | 19/06/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of efgartigimod alfa compared with the current standard of care. |
| Full HTA commissioned by the HSE | 28/06/2023 |
| Pre-submission consultation with Applicant | 07/11/2023 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.